, Singapore
618 views
Photo from Shutterstock

Rohto and Mitsui lead acquisition of Eu Yan Sang for $695M

The Japanese companies acquired an 86% stake in the company.

A consortium led by Japanese companies Rohto Pharmaceutical and Mitsui & Co. has acquired Singapore-based traditional Chinese medicine company Eu Yan Sang International (EYSI) for $695m.

The consortium acquired an 86% stake from Righteous Crane Holding (RCH).

RCH is an investment holding company owned by Tower Capital Asia subsidiary, Tower Capital TCM Holdings, and Temasek Holdings unit Blanca Investments.

“In 2016, we chose to partner with Tower Capital Asia due to their understanding of the Eu Yan Sang heritage and commitment to driving excellence. Tower Capital Asia, together with Temasek, was instrumental in elevating the EYSI brand, institutionalising operations, and establishing the foundation for our next chapter as a natural health and wellness brand,"  said Richard Eu, chairman of EYSI.
 

Follow the link for more news on

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.


If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.